Sources of Patients' Knowledge of the Adverse Effects of Psychotropic Medication and the Perceived Influence of Adverse Effects on Compliance Among Service Users Attending Community Mental Health Services

Agyapong, Vincent Israel Opoku; Nwankwo, Vincent; Bangaru, Raju; Kirrane, R.

doi:10.1097/jcp.0b013e3181befa3e

Cited by 14 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before patients are initiated on CFTR modulators, pharmacists can provide the necessary counseling and education. Patients who are informed about potential AEs in advance may be more willing to trial a new medication [123,124], especially if strategies to address potential AEs are provided [123]. Anecdotally, this has been true at our site: some patients have expressed hesitancy and concern about potential AEs secondary to CFTR modulators, but once monitoring and strategies to address potential AE were discussed, they were more open to a trial.…”

Section: Patient Counseling and Educationmentioning

confidence: 99%

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review

Dagenais

Quon

2020

JCM

View full text Add to dashboard Cite

Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies target the underlying cause of cystic fibrosis (CF), and are generally well-tolerated; however, real-world studies indicate the frequency of discontinuation and adverse events (AEs) may be higher than what was observed in clinical trials. The objectives of this systematic review were to summarize real-world AEs reported for market-available CFTR modulators (i.e., ivacaftor (IVA), lumacaftor/ivacaftor (LUM/IVA), tezacaftor/ivacaftor (TEZ/IVA), and elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA)), and to identify ways in which the pharmacist on CF healthcare teams may contribute to mitigating and managing these AEs. The MEDLINE, EMBASE, CINAHL, and Web of Science Core Collection online databases were searched from 2012 to 1 Aug 2020. Full manuscripts or conference abstracts of observational studies, case series, and case reports were eligible for inclusion. The included full manuscripts and conference abstracts comprised of 54 observational studies, 5 case series, and 9 case reports. The types of AEs reported generally aligned with what have been observed in clinical trials. LUM/IVA was associated with a higher frequency of respiratory-related AE and discontinuation in real-world studies. A signal for mental health and neurocognitive AEs was identified with all 4 CFTR modulators. A systematic approach to monitoring for AEs in people with CF on CFTR modulators in the real-world setting is necessary to help better understand potential AEs, as well as patient characteristics that may be associated with higher risk of certain AEs. Pharmacists play a key role in the safe initiation and monitoring of people with CF on CFTR modulator therapies.

show abstract

Section: Patient Counseling and Educationmentioning

confidence: 99%

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review

Dagenais

Quon

2020

JCM

View full text Add to dashboard Cite

show abstract

“…Lack of such knowledge is widespread and a prevailing source of dissatisfaction among patients with BD[75,101,106,113,127,128]. Patients appear particularly unhappy with the lack of information provided on side effects and other aspects related to medication-treatment[75,86,127-129]. Although enhancing knowledge should improve adherence among patients, results of studies in BD have been somewhat equivocal in this regard.…”

Section: Patient-centred Determinants Of Non-adherence In Bdmentioning

confidence: 99%

Treatment-adherence in bipolar disorder: A patient-centred approach

Chakrabarti

2016

WJP

View full text Add to dashboard Cite

About half of the patients diagnosed with bipolar disorder (BD) become non-adherent during long-term treatment, a rate largely similar to other chronic illnesses and one that has remained unchanged over the years. Non-adherence in BD is a complex phenomenon determined by a multitude of influences. However, there is considerable uncertainty about the key determinants of non-adherence in BD. Initial research on non-adherence in BD mostly limited itself to examining demographic, clinical and medication-related factors impacting adherence. However, because of inconsistent results and failure of these studies to address the complexities of adherence behaviour, demographic and illness-related factors were alone unable to explain or predict non-adherence in BD. This prompted a shift to a more patient-centred approach of viewing non-adherence. The central element of this approach includes an emphasis on patients’ decisions regarding their own treatment based on their personal beliefs, life circumstances and their perceptions of benefits and disadvantages of treatment. Patients’ decision-making processes are influenced by the nature of their relationship with clinicians and the health-care system and by people in their immediate environment. The primacy of the patient’s perspective on non-adherence is in keeping with the current theoretical models and concordance-based approaches to adherence behaviour in BD. Research over the past two decades has further endorsed the critical role of patients’ attitudes and beliefs regarding medications, the importance of a collaborative treatment-alliance, the influence of the family, and the significance of other patient-related factors such as knowledge, stigma, patient satisfaction and access to treatment in determining non-adherence in BD. Though simply moving from an illness-centred to a patient-centred approach is unlikely to solve the problem of non-adherence in BD, such an approach is more likely to lead to a better understanding of non-adherence and more likely to yield effective solutions to tackle this common and distressing problem afflicting patients with BD.

show abstract

“…10,14,17,18 Patients are looking for information, [19][20][21][22][23][24][25][26][27][28] particularly about adverse effects. [29][30][31][32][33] However, studies have shown that physicians provide little information regarding pharmacological treatments. [34][35][36][37][38] According to the patient medication-taking practice model developed by Bajcar, making "sense of the purpose" of the medication is of significant importance for adherence.…”

Section: Introductionmentioning

confidence: 99%

Optimizing Communication About Topical Corticosteroids: A Quality Improvement Study

et al. 2020

View full text Add to dashboard Cite

Background Patients are often non-adherent to topical corticosteroids (TCS). This may be in part due to poor communication between patients and dermatologists. Objectives This quality improvement (QI) study aims to describe dermatologist–patient communication about TCS treatments and to compare communication before and after the implementation of an educational intervention. Methods This QI study assesses the communication between dermatologists and new dermatology outpatients receiving a TCS prescription in a tertiary care center. The QI intervention is 2-pronged, consisting of an educational pamphlet for patients and a communication workshop for the dermatology team. Encounters were audiotaped, and communication was analyzed using a coding system (MEDICODE). Phase 1 recordings happened preintervention and reflect the usual dermatologist–patient communication in this practice setting and phase 2 recordings were postintervention. Results Phase 1 reveals that dermatologists frequently address informational medication themes, such as naming the medications and informing patients about their proper use. They less frequently discuss patient experience themes, such as goals of treatment, adverse effects of treatments, and exploring patients’ emotions about medications (such as anxiety, fears, etc.). After the intervention, there was more frequent discussion of patient experience themes without increasing consultation length. But, in both phases, physicians address most themes as a monolog with little verbal input from patients. Conclusions Our study raises awareness regarding dermatologists’ communication patterns about TCS, identifying specific areas for improvement, such as discussions of adverse effects, and explicitly addressing patients’ attitudes and emotions. This is an essential step to foster a sense-making of TCS for patients.

show abstract

Sources of Patients' Knowledge of the Adverse Effects of Psychotropic Medication and the Perceived Influence of Adverse Effects on Compliance Among Service Users Attending Community Mental Health Services

Cited by 14 publications

References 15 publications

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review

Treatment-adherence in bipolar disorder: A patient-centred approach

Optimizing Communication About Topical Corticosteroids: A Quality Improvement Study

Contact Info

Product

Resources

About